Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows

Haematologica

Volumn 92, Issue 5, 2007, Pages 597-604

  Zetterberg, Eva ^a   Vannucchi, Alessandro M ^b   Migliaccio, Anna Rita ^c   Vainchenker, William ^d   Tulliez, Micheline ^e   Dickie, Renée ^f   Hasselbaich, Hans ^g   Rogers, Rick ^f   Palmblad, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF FLORENCE   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Hôpital Cochin ^*  (France)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Angiogenesis; Microvascular density; Myelofibrosis; Pericytes; SMA

Indexed keywords

THROMBOPOIETIN; TRANSCRIPTION FACTOR GATA 1; ACTIN; BIOLOGICAL MARKER; HYBRID PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BONE MARROW; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC DISORDER; HUMAN; HUMAN TISSUE; MALE; MEGAKARYOCYTE; MICROVASCULATURE; MOUSE; MYELOFIBROSIS; NONHUMAN; PATHOGENESIS; PERICYTE; SPLEEN; WILD TYPE; ANIMAL; BIOSYNTHESIS; CAPILLARY; CHEMISTRY; DISEASE MODEL; FIBROSIS; GENETICS; IMMUNOLOGY; MIDDLE AGED; MOUSE MUTANT; MYELOID METAPLASIA; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RADIATION CHIMERA; STROMA CELL; VASCULARIZATION;

ACTINS; AGED; AGED, 80 AND OVER; ANIMALS; BIOLOGICAL MARKERS; BONE MARROW; CAPILLARIES; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; GATA1 TRANSCRIPTION FACTOR; HUMANS; MALE; MEGAKARYOCYTES; MICE; MICE, KNOCKOUT; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; RADIATION CHIMERA; RECOMBINANT FUSION PROTEINS; SPLEEN; STROMAL CELLS; THROMBOPOIETIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 34347393001     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11013     Document Type: Article

References (37)

1. Folkman J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev 1990;9:171-4.
2. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815-21.
3. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000;157:15-9.
4. Korkolopoulou P, Viniou N, Kavantzas N, et al. Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia 2003;17:89-97.
5. Kvasnicka HM, Thiele J, Staib P. Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 2004;103:3549-51.
6. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998;282:468-71.
7. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003; 314: 15-23.
8. Sorrell JM. Development of arteries in embryonic chick bone marrow with special reference to the appearance of periarterial granulopoietic sheaths. Anat Rec 1988;221:730-6.
9. Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 1994;8:1875-87.
10. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-93.
11. Ozawa MG, Yao VJ, Chanthery YH, et ai. Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer 2005; 104:2104-15.
12. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendung F. Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002;100:3495-503.
13. Yan XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 1996; 88:402-9.
14. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108:3472-6.
15. Vannucchi AM, Bianchi L, Cellai C, Paoletti F, Rana RA, Lorenzini R, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-llow mice). Blood 2002;100:1123-32.
16. Vannucchi AM, Bianchi L, Paoletti F, Di Giacomo V, Migliaccio G, Migliaccio AR. Impaired GATA-1 expression and myelofibrosis in an animal model. Pathol Biol (Paris). 2004; 52:275-9
17. Amital H, Rewald E, Levy Y, BarDayan Y, Manthorpe R, Engervall P, et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 2003;62:175-7.
18. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. Embo J 1997;16:3965-73.
19. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93:2357-64.
20. Zetterberg E, Lundberg LG, Palmblad J. Characterization of blood vessels in bone marrow from patients with chronic myeloid leukemia and polycythemia vera. Scand J Clin Lab Invest 2004;64:641-7.
21. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003;45:227-44.
22. Ho CL AB, Hoyer JD, Wellik LE, Mesa RA, Tefferi A. Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia. Eur J Haematol 2005;74:35-9.
23. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 2004;15:215-28.
24. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999; 93: 2627-36.
25. Valdembri D, Serini G, Vacca A, Ribatti D, Bussolino F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. Faseb J 2002;16:225-7.
26. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Nad Acad Sci USA 1997;94:8761-6.
27. Vikkula M, Boon LM, Carraway KL, 3rd, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996;87:1181-90.
28. Wrobel T, Mazur G, Surowiak P, Wolowiec D, Jelen M, Kuliczkowsky K. Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD). Pathol Oncol Res 2003;9:170-3.
29. Ni H, Barosi G, Hoffman R. Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. Am J Clin Pathol 2006;126: 241-7.
30. Chou JM, Li CY, Tefferi A. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia. Leuk Res 2003; 27:499-504.
31. Sundberg C, Ivarsson M, Gerdin B, Rubin K. Pericytes as collagen-producing cells in excessive dermal scarring. Lab Invest 1996;74:452-66.
32. Sims DE. Diversity within pericytes. Clin Exp Pharmacol Physiol 2000; 27:842-6.
33. Abramsson A, Berlin O, Papayan H, Paulin D, Shard M, Betsholtz C. Analysis of mural cell recruitment to tumor vessels. Circulation 2002; 105: 112-7.
34. Reilly JT, Barnett D, Dolan G, Forrest P, Eastham J, Smith A. Characterization of an acute micromegakaryocytic leukaemia: evidence for the pathogenesis of myelofibrosis. Br J Haematol 1993;83:58-62.
35. Kimura A, Katoh O, Hyodo H, Kuramoto A, Satow Y. Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia. Leuk Lymphoma 1995;18: 237-42.
36. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 2004; 18:338-40.
37. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor b in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-8.